![PSA Testing for the Pretreatment Staging and Posttreatment Management of Prostate Cancer - American Urological Association PSA Testing for the Pretreatment Staging and Posttreatment Management of Prostate Cancer - American Urological Association](https://www.auanet.org/images/Education/clinical-guidance/Prostate-Specific-Antigen-Figure-2.jpg)
PSA Testing for the Pretreatment Staging and Posttreatment Management of Prostate Cancer - American Urological Association
![Frontiers | Prostate-Specific Antigen Trends Predict the Probability of Prostate Cancer in a Very Large U.S. Veterans Affairs Cohort Frontiers | Prostate-Specific Antigen Trends Predict the Probability of Prostate Cancer in a Very Large U.S. Veterans Affairs Cohort](https://www.frontiersin.org/files/MyHome%20Article%20Library/373093/373093_Thumb_400.jpg)
Frontiers | Prostate-Specific Antigen Trends Predict the Probability of Prostate Cancer in a Very Large U.S. Veterans Affairs Cohort
Biochemical recurrence after radical prostatectomy according to nadir prostate specific antigen value | PLOS ONE
![PSA course over time in men with prostate cancer and BPH.Screening can... | Download Scientific Diagram PSA course over time in men with prostate cancer and BPH.Screening can... | Download Scientific Diagram](https://www.researchgate.net/publication/233941394/figure/fig1/AS:278879039180841@1443501352903/PSA-course-over-time-in-men-with-prostate-cancer-and-BPHScreening-can-bring-forward.png)
PSA course over time in men with prostate cancer and BPH.Screening can... | Download Scientific Diagram
![mCRPC patients with PSA fluctuations under radioligand therapy have comparable survival benefits relative to patients with sustained PSA decrease | SpringerLink mCRPC patients with PSA fluctuations under radioligand therapy have comparable survival benefits relative to patients with sustained PSA decrease | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs00259-022-05910-w/MediaObjects/259_2022_5910_Fig3_HTML.png)
mCRPC patients with PSA fluctuations under radioligand therapy have comparable survival benefits relative to patients with sustained PSA decrease | SpringerLink
![mCRPC patients with PSA fluctuations under radioligand therapy have comparable survival benefits relative to patients with sustained PSA decrease | SpringerLink mCRPC patients with PSA fluctuations under radioligand therapy have comparable survival benefits relative to patients with sustained PSA decrease | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs00259-022-05910-w/MediaObjects/259_2022_5910_Fig4_HTML.png)
mCRPC patients with PSA fluctuations under radioligand therapy have comparable survival benefits relative to patients with sustained PSA decrease | SpringerLink
The effect of 3-month finasteride challenge on biomarkers for predicting cancer outcome on biopsy: Results of a randomized trial | PLOS ONE
A Tissue Biomarker Panel Predicting Systemic Progression after PSA Recurrence Post-Definitive Prostate Cancer Therapy | PLOS ONE
![Changes in serum PSA levels after undergoing salvage radiotherapy. (A)... | Download Scientific Diagram Changes in serum PSA levels after undergoing salvage radiotherapy. (A)... | Download Scientific Diagram](https://www.researchgate.net/publication/324966658/figure/fig1/AS:789302996922368@1565195907985/Changes-in-serum-PSA-levels-after-undergoing-salvage-radiotherapy-A-Successful-SRT-was_Q640.jpg)
Changes in serum PSA levels after undergoing salvage radiotherapy. (A)... | Download Scientific Diagram
![The graph shows the relationship between age and PSA (on a log scale)... | Download Scientific Diagram The graph shows the relationship between age and PSA (on a log scale)... | Download Scientific Diagram](https://www.researchgate.net/publication/230736028/figure/fig1/AS:601804685455360@1520492826116/The-graph-shows-the-relationship-between-age-and-PSA-on-a-log-scale-with-a-cubic-spline.png)
The graph shows the relationship between age and PSA (on a log scale)... | Download Scientific Diagram
![Use of early PSA velocity to predict eventual abnormal PSA values in men at risk for prostate cancer | Prostate Cancer and Prostatic Diseases Use of early PSA velocity to predict eventual abnormal PSA values in men at risk for prostate cancer | Prostate Cancer and Prostatic Diseases](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fsj.pcan.4500614/MediaObjects/41391_2003_Article_BF4500614_Fig1_HTML.gif)
Use of early PSA velocity to predict eventual abnormal PSA values in men at risk for prostate cancer | Prostate Cancer and Prostatic Diseases
![Cancers | Free Full-Text | Definition of Outcome-Based Prostate-Specific Antigen (PSA) Thresholds for Advanced Prostate Cancer Risk Prediction Cancers | Free Full-Text | Definition of Outcome-Based Prostate-Specific Antigen (PSA) Thresholds for Advanced Prostate Cancer Risk Prediction](https://www.mdpi.com/cancers/cancers-13-03381/article_deploy/html/images/cancers-13-03381-g001.png)
Cancers | Free Full-Text | Definition of Outcome-Based Prostate-Specific Antigen (PSA) Thresholds for Advanced Prostate Cancer Risk Prediction
![Prostate-Specific Antigen Testing: Overview, Physiologic Characteristics of PSA, Other Prostate Cancer Markers Prostate-Specific Antigen Testing: Overview, Physiologic Characteristics of PSA, Other Prostate Cancer Markers](https://img.medscapestatic.com/pi/meds/ckb/09/23509tn.jpg)
Prostate-Specific Antigen Testing: Overview, Physiologic Characteristics of PSA, Other Prostate Cancer Markers
![Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL | Prostate Cancer and Prostatic Diseases Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL | Prostate Cancer and Prostatic Diseases](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fpcan.2016.71/MediaObjects/41391_2017_Article_BFpcan201671_Fig1_HTML.jpg)
Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL | Prostate Cancer and Prostatic Diseases
![mCRPC patients with PSA fluctuations under radioligand therapy have comparable survival benefits relative to patients with sustained PSA decrease | SpringerLink mCRPC patients with PSA fluctuations under radioligand therapy have comparable survival benefits relative to patients with sustained PSA decrease | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs00259-022-05910-w/MediaObjects/259_2022_5910_Fig2_HTML.png)
mCRPC patients with PSA fluctuations under radioligand therapy have comparable survival benefits relative to patients with sustained PSA decrease | SpringerLink
![mCRPC patients with PSA fluctuations under radioligand therapy have comparable survival benefits relative to patients with sustained PSA decrease | SpringerLink mCRPC patients with PSA fluctuations under radioligand therapy have comparable survival benefits relative to patients with sustained PSA decrease | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs00259-022-05910-w/MediaObjects/259_2022_5910_Fig1_HTML.png)